These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14567642)

  • 1. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
    Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN
    Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides.
    Holm R; Porter CJ; Edwards GA; Müllertz A; Kristensen HG; Charman WN
    Eur J Pharm Sci; 2003 Sep; 20(1):91-7. PubMed ID: 13678797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.
    Caliph SM; Charman WN; Porter CJ
    J Pharm Sci; 2000 Aug; 89(8):1073-84. PubMed ID: 10906731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
    Khoo SM; Prankerd RJ; Edwards GA; Porter CJ; Charman WN
    J Pharm Sci; 2002 Mar; 91(3):647-59. PubMed ID: 11920750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
    Khoo SM; Edwards GA; Porter CJ; Charman WN
    J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
    Porter CJ; Charman SA; Charman WN
    J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.
    Holm R; Porter CJ; Müllertz A; Kristensen HG; Charman WN
    Pharm Res; 2002 Sep; 19(9):1354-61. PubMed ID: 12403073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?
    Shackleford DM; Porter CJ; Charman WN
    Biopharm Drug Dispos; 2003 May; 24(4):153-7. PubMed ID: 12698498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.
    Holm R; Müllertz A; Pedersen GP; Kristensen HG
    Pharm Res; 2001 Sep; 18(9):1299-304. PubMed ID: 11683243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.
    Karpf DM; Holm R; Kristensen HG; Müllertz A
    Pharm Res; 2004 Aug; 21(8):1413-8. PubMed ID: 15359576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.
    Trevaskis NL; Caliph SM; Nguyen G; Tso P; Charman WN; Porter CJ
    Pharm Res; 2013 Dec; 30(12):3254-70. PubMed ID: 23430484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
    White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic transport of puerarin occurs after oral administration of different lipid-based formulations to unconscious lymph duct-cannulated rats.
    Zhou A; Lu T; Wang L; Lu C; Wang L; Wan M; Wu H
    Pharm Dev Technol; 2014 Sep; 19(6):743-7. PubMed ID: 23978005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems.
    Wu H; Zhou A; Lu C; Wang L
    Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat.
    Trevaskis NL; Porter CJ; Charman WN
    Drug Metab Dispos; 2006 May; 34(5):729-33. PubMed ID: 16467133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
    Lind ML; Jacobsen J; Holm R; Müllertz A
    Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
    Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
    Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
    Caliph SM; Trevaskis NL; Charman WN; Porter CJ
    J Pharm Sci; 2012 Sep; 101(9):3540-6. PubMed ID: 22623170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport.
    Trevaskis NL; Porter CJ; Charman WN
    J Pharmacol Exp Ther; 2006 Feb; 316(2):881-91. PubMed ID: 16249368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal lymphatic drug transport: an update.
    Porter CJ; Charman WN
    Adv Drug Deliv Rev; 2001 Aug; 50(1-2):61-80. PubMed ID: 11489334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.